# CRISPR Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/crispr-therapeutics

- Industry: Biotechnology
- Headquarters: Zug, Switzerland
- Website: www.crisprtx.com/
- Total disclosed funding: $127M
- Latest round: Series B (Jun 24, 2016)
- Investors on record: 9

## About

CRISPR Therapeutics AG, based in Switzerland, is a leading biotechnology firm specializing in transformative gene-based medicines through CRISPR technology. It develops advanced therapies for various genetic disorders, including sickle cell disease and beta-thalassemia.CRISPR Therapeutics AG focuses on developing gene-editing solutions for serious diseases. Founded in 2013 in Zug, Switzerland, the company has engaged in 7 deals since its IPO in October 2016, which initially raised USD 56 mn. The most recent funding occurred on July 6, 2020, through a Private Placement/Follow on, raising USD 517.50 mn. The CEO is Samarth Kulkarni.CRISPR Therapeutics develops gene-based medicines using CRISPR technology. Its notable product, CASGEVY™ (exagamglogene autotemcel), is approved for treating sickle cell disease and transfusion-dependent beta-thalassemia. The company is advancing multiple clinical programs targeting hemoglobinopathies, oncology, diabetes, and cardiovascular diseases, with innovative therapies aimed at treating cancer and autoimmune conditions.In 2023, CRISPR Therapeutics reported a revenue of USD 371.21 mn and an EBITDA of USD -202.70 mn. The company primarily generates revenue through its approved therapies, particularly CASGEVY™, and collaborations with pharmaceutical partners, including Vertex Pharmaceuticals, which involve structured financial agreements.CRISPR Therapeutics plans to expand its product offerings and market reach in the coming years. Following the recent funding of USD 517.50 mn in July 2020, the company aims to accelerate the development of new therapies and explore entry into new geographic markets. It focuses on advancing its pipeline of gene-editing solutions for various diseases, with ongoing clinical programs that may lead to additional product launches in the near future.

## Funding rounds

- Series B, Jun 24, 2016, $38M — New Leaf Venture Partners, Wellington Capital Advisory, Franklin Templeton, Clough Capital Partners
- Series B, Apr 29, 2015, $29M — Abingworth, New Enterprise Associates, Versant Ventures, SR One, Bristol-Myers Squibb Company
- Series A, Apr 28, 2015, $35M — Abingworth, New Enterprise Associates, Versant Ventures, SR One, Bristol-Myers Squibb Company
- Series A, Apr 24, 2014, $25M — Versant Ventures

## Investors

- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A, Series B
- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series A, Series B
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A, Series B
- SR One (https://capitalatlas.ai/funds/sr-one) — Series A, Series B
- Bristol-Myers Squibb Company — Series A, Series B
- New Leaf Venture Partners (https://capitalatlas.ai/funds/new-leaf-venture-partners) — Series B
- Wellington Capital Advisory (https://capitalatlas.ai/funds/wellington-capital-advisory) — Series B
- Franklin Templeton (https://capitalatlas.ai/funds/franklin-templeton) — Series B
- Clough Capital Partners — Series B